Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Researchers from the Cleveland Clinic say that people who’ve already had COVID-19 may not necessarily benefit from vaccination.

A new study from the Cleveland Clinic in Ohio has found that people who’ve already had COVID-19 may not necessarily benefit from vaccination.

The research indicates that out of a large pool of healthcare workers, there were nearly 0 cases of SARS-CoV-2 infection among those who had:

-previously contracted the virus and were unvaccinated
-previously contracted the virus and were vaccinated
-never contracted the virus and were vaccinated

There was, however, a steady increase in cases among unvaccinated people who hadn’t previously contracted SARS-CoV-2.

According to the researchers, the findings suggest that natural infection provides immunity similar to vaccination. Therefore, people who haven’t had COVID-19 can be prioritized for vaccination.

Experts say that more research is needed to determine how long immunity lasts after a case of COVID-19. Until we have that data, some infectious disease specialists are recommending that people who’ve had COVID-19 still get one dose.

Source: Healthline

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!